Nautilus Biotechnology Shifts R&D Focus Toward Proteoform Applications Amid Broadscale Delays
Nautilus Biotechnology (NASDAQ:NAUT) is reallocating most of its research and development resources to proteoform applications due to strong customer demand, while significantly reducing the size of its Broadscale team. The company now expects delays in achieving general availability for the Broadscale program beyond 2027 without a revised timeline provided. Nautilus reported $0.2 million in first-quarter revenue and a net loss of $14.5 million, with cash reserves totaling $129.2 million as of Q2 2026. Management anticipates these funds will last through early 2028 but expects to raise additional capital by mid-2027. The company plans multiple proteoform assays for commercial availability in the coming years, including AKT1 oncology and tau assays expected in mid-2027. The shift reflects a strategic pivot toward higher-value applications where Nautilus can offer differentiated capabilities based on customer feedback.
Tickers: $NAUT